PTC THERAPEUTICS INC's ticker is PTCT and the CUSIP is 69366J200. A total of 185 filers reported holding PTC THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $272,927 | -32.0% | 8,925 | -35.3% | 0.13% | -37.1% |
Q1 2024 | $401,587 | +23.3% | 13,805 | +16.8% | 0.21% | +2.9% |
Q4 2023 | $325,732 | +105.4% | 11,819 | +67.1% | 0.21% | +115.6% |
Q3 2023 | $158,551 | -51.2% | 7,075 | -11.4% | 0.10% | -50.3% |
Q2 2023 | $324,913 | -13.8% | 7,989 | +2.6% | 0.19% | -6.8% |
Q1 2023 | $377,057 | +29.2% | 7,784 | +1.8% | 0.21% | +36.2% |
Q4 2022 | $291,924 | -36.7% | 7,648 | -16.7% | 0.15% | -17.4% |
Q3 2022 | $461,000 | +27.3% | 9,177 | +1.5% | 0.18% | +37.3% |
Q2 2022 | $362,000 | -3.2% | 9,043 | -9.9% | 0.13% | -19.8% |
Q1 2022 | $374,000 | -6.5% | 10,034 | 0.0% | 0.17% | +10.6% |
Q4 2021 | $400,000 | +3.1% | 10,034 | -3.7% | 0.15% | -11.7% |
Q3 2021 | $388,000 | -19.3% | 10,416 | -8.4% | 0.17% | -13.6% |
Q2 2021 | $481,000 | +7.1% | 11,368 | +20.0% | 0.20% | +4.2% |
Q1 2021 | $449,000 | -20.2% | 9,476 | +2.8% | 0.19% | -18.8% |
Q4 2020 | $563,000 | +1.4% | 9,220 | -22.3% | 0.23% | -19.6% |
Q3 2020 | $555,000 | +0.7% | 11,863 | +9.2% | 0.29% | +11.5% |
Q2 2020 | $551,000 | +1.3% | 10,864 | -10.9% | 0.26% | +16.5% |
Q1 2020 | $544,000 | -14.3% | 12,197 | -7.8% | 0.22% | +115.4% |
Q4 2019 | $635,000 | +198.1% | 13,226 | +109.7% | 0.10% | +141.9% |
Q3 2019 | $213,000 | -29.0% | 6,308 | -5.3% | 0.04% | -31.7% |
Q2 2019 | $300,000 | +0.3% | 6,660 | -16.2% | 0.06% | -90.1% |
Q1 2019 | $299,000 | +0.7% | 7,947 | -8.1% | 0.64% | +1147.1% |
Q4 2018 | $297,000 | -48.7% | 8,648 | -29.8% | 0.05% | -15.0% |
Q3 2018 | $579,000 | -18.8% | 12,326 | -41.7% | 0.06% | -90.5% |
Q2 2018 | $713,000 | -43.9% | 21,140 | -54.9% | 0.63% | -42.8% |
Q1 2018 | $1,270,000 | +249.9% | 46,917 | +115.7% | 1.10% | +141.7% |
Q4 2017 | $363,000 | -7.4% | 21,752 | +10.9% | 0.46% | +760.4% |
Q3 2017 | $392,000 | +19.9% | 19,612 | +10.1% | 0.05% | +8.2% |
Q2 2017 | $327,000 | +46.6% | 17,818 | -21.5% | 0.05% | +22.5% |
Q1 2017 | $223,000 | -0.4% | 22,699 | +10.6% | 0.04% | -40.3% |
Q4 2016 | $224,000 | -54.1% | 20,523 | -41.1% | 0.07% | -71.6% |
Q3 2016 | $488,000 | +99.2% | 34,849 | 0.0% | 0.24% | +29.7% |
Q2 2016 | $245,000 | +329.8% | 34,849 | +297.0% | 0.18% | +130.4% |
Q1 2016 | $57,000 | – | 8,777 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Asymmetry Capital Management, L.P. | 110,794 | $3,802,000 | 10.50% |
Boxer Capital, LLC | 2,155,000 | $73,960,000 | 9.14% |
RTW INVESTMENTS, LP | 1,922,346 | $65,975,000 | 6.14% |
GREAT POINT PARTNERS LLC | 1,225,000 | $42,042,000 | 5.31% |
Opaleye Management Inc. | 190,000 | $6,520,000 | 2.43% |
SCOPIA CAPITAL MANAGEMENT LP | 1,626,965 | $55,837,000 | 1.89% |
SPHERA FUNDS MANAGEMENT LTD. | 345,500 | $11,858,000 | 1.34% |
SECTORAL ASSET MANAGEMENT INC | 233,536 | $8,015,000 | 1.09% |
Elk Creek Partners, LLC | 377,674 | $12,962,000 | 1.08% |
Orbimed Advisors | 1,519,700 | $52,156,000 | 0.96% |